Clinical trial
An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma
NCT03006926 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma
- Lead sponsor
- Eisai Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 13, 2017
- Completion date
- November 22, 2022
- Enrollment
- 104 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma